Mirati Therapeutics, Inc. (MRTX) Given Average Recommendation of “Hold” by Brokerages
Mirati Therapeutics, Inc. (NASDAQ:MRTX) has been assigned an average rating of “Hold” from the nine brokerages that are presently covering the firm. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $13.07.
MRTX has been the subject of a number of research analyst reports. HC Wainwright set a $10.00 target price on Mirati Therapeutics and gave the company a “buy” rating in a research note on Saturday, March 11th. Zacks Investment Research raised Mirati Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 target price for the company in a research note on Wednesday, May 3rd. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $5.50 target price on shares of Mirati Therapeutics in a research note on Wednesday, April 12th.
Hedge funds and other institutional investors have recently bought and sold shares of the company. KCG Holdings Inc. purchased a new position in Mirati Therapeutics during the first quarter valued at $106,000. Teachers Advisors LLC boosted its position in Mirati Therapeutics by 22.9% in the first quarter. Teachers Advisors LLC now owns 23,097 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 4,311 shares in the last quarter. Trexquant Investment LP boosted its position in Mirati Therapeutics by 21.1% in the fourth quarter. Trexquant Investment LP now owns 26,432 shares of the biotechnology company’s stock valued at $126,000 after buying an additional 4,599 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Mirati Therapeutics by 22.9% in the first quarter. Bank of New York Mellon Corp now owns 63,004 shares of the biotechnology company’s stock valued at $328,000 after buying an additional 11,753 shares in the last quarter. Finally, Omega Advisors Inc. purchased a new position in Mirati Therapeutics during the first quarter valued at $520,000. 50.41% of the stock is owned by institutional investors.
Shares of Mirati Therapeutics (NASDAQ:MRTX) opened at 3.60 on Friday. The stock’s market capitalization is $89.78 million. Mirati Therapeutics has a 52 week low of $3.10 and a 52 week high of $19.25. The company has a 50-day moving average price of $4.31 and a 200 day moving average price of $5.17.
Mirati Therapeutics (NASDAQ:MRTX) last posted its earnings results on Thursday, March 9th. The biotechnology company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by $0.02. Analysts forecast that Mirati Therapeutics will post ($3.31) earnings per share for the current fiscal year.
Mirati Therapeutics Company Profile
Receive News & Stock Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related stocks with our FREE daily email newsletter.